Tempus ECG-AF vs 1CMR Pro

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

1CMR Pro

by Mycardium AI Limited

AI Verdict

Tempus ECG-AF is an AI tool focused on predicting the risk of new-onset atrial fibrillation in older patients by analyzing 12-lead ECGs. In contrast, 1CMR Pro is an AI-enhanced software designed to improve the precision and speed of cardiac MRI reporting and analysis. While both operate in cardiology, they address different diagnostic modalities and distinct clinical objectives, making them adjacent rather than direct competitors.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging standard 12-lead ECG recordings. This tool is particularly valuable for early risk stratification in a broad elderly population, enabling timely intervention and follow-up care.

View Tempus ECG-AF →

Choose 1CMR Pro if…

Choose 1CMR Pro if your cardiology or radiology department requires highly precise, automated, and consistent analysis of Cardiac MRI scans for detailed diagnostic and treatment planning. This software is ideal for institutions aiming to enhance the accuracy of volumetric and functional measurements, streamline reporting workflows, and ensure reproducibility in cardiac MRI interpretation.

View 1CMR Pro →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	1CMR Pro
Pricing	Contact vendor	Contact for pricing
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	On-premise (software installed on hospital's own computer, processing data locally via a secure web-based platform)
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

1CMR Pro

While both tools integrate into existing healthcare workflows, 1CMR Pro explicitly highlights 'transparent and editable contours for clinician control'. This feature suggests a more interactive and clinician-empowering user experience, allowing for direct review and adjustment of AI outputs, which enhances trust and usability in a clinical setting.

Clinical Value

1CMR Pro

Both are FDA-cleared and offer significant clinical benefits. However, 1CMR Pro quantifies its improvement with 'up to 40% more precise measurements' and was found 'superior to humans for all measurements' in precision testing, which is a strong, measurable indicator of enhanced diagnostic accuracy and consistency. Tempus ECG-AF offers valuable early risk identification, but 1CMR Pro's direct impact on measurement precision is a more concrete and quantifiable clinical advantage.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing a transparent and established pathway for financial viability for healthcare providers. 1CMR Pro's pricing is not publicly disclosed, making its value proposition less clear from a financial perspective.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF explicitly states 'has_baa: yes' and 'hipaa_compliant: yes,' alongside FDA clearance and integration capabilities. While 1CMR Pro mentions local data processing and ISO 27001, its lack of an explicit BAA statement and a 'likely' HIPAA compliance status makes Tool A appear more robustly prepared for enterprise deployment and regulatory scrutiny.

Innovation

Tie

Both tools demonstrate significant innovation by applying AI to complex cardiology challenges. Tempus ECG-AF offers a novel predictive risk assessment for AF from standard ECGs, while 1CMR Pro leverages advanced convolutional neural networks to achieve a substantial and quantifiable increase in precision for Cardiac MRI analysis. Both represent cutting-edge applications of AI in their respective domains.

Support & Docs

Tempus ECG-AF

Tempus ECG-AF provides explicit contact information (email and phone number) for its Cardiology Support team in publicly available FDA documentation, offering clear channels for assistance. While 1CMR Pro mentions 'dedicated customer support' on its website, it does not provide similar direct contact details publicly, making Tempus's support access more transparent.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	1CMR Pro
Product Name	Tempus ECG-AF	1CMR Pro
Company	Tempus AI, Inc.	Mycardium AI Limited
Target Modality/Data Type	12-lead ECG recordings	Cardiac MRI
Primary Function	Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.	AI-enhanced Cardiac MRI reporting software for faster and more consistent analysis, delivering up to 40% more precise measurements.
Target Patient Population	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.	Not specified
Key AI Training Data	Trained on over 1.5 million ECGs from over 500,000 patients.	Convolutional neural networks trained on extensive datasets (700,000 cine images, 60,000 expert segmentations).

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and 1CMR Pro.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application and target patient population for each tool?

Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. 1CMR Pro is an FDA 510(k) cleared and CE Class IIB cleared AI-enhanced Cardiac MRI reporting software that delivers up to 40% more precise measurements, enabling faster and more consistent cardiac MRI analysis.

What type of imaging data does each tool analyze?

Tempus ECG-AF analyzes 12-lead ECG recordings and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. 1CMR Pro is specifically an AI-enhanced Cardiac MRI reporting software, utilizing Cardiac MRI images for automated volumetric and functional measurements.

How do these tools handle patient data and ensure privacy?

Tempus ECG-AF is HIPAA compliant and has a Business Associate Agreement (BAA). 1CMR Pro is deployed on-premise, with the software installed on the hospital's own computer and processing data locally via a secure web-based platform, ensuring no patient data is transmitted beyond the institution.

What are the regulatory clearances for each tool?

Tempus ECG-AF is an FDA-cleared AI-based algorithm. 1CMR Pro is both FDA 510(k) cleared and CE Class IIB cleared.

Is there established reimbursement for using these tools?

Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90, effective January 1, 2025. Reimbursement details for 1CMR Pro are not publicly disclosed.

What are the key performance claims or benefits of each tool?

Tempus ECG-AF supports earlier identification and follow-up for patients at increased risk of new-onset AF within 12 months. 1CMR Pro delivers up to 40% more precise measurements than manual analysis, enabling faster and more consistent cardiac MRI analysis.